---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007036"
form_type: "8-K"
ticker: "IRIX"
cik: "0001006045"
company_name: "IRIDEX CORP"
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T06:12:28.987305+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Iridex Q4 revenue flat at $15.2M; record glaucoma probe sales; FY net loss widens to $7.5M

## Summary
- Q4 revenue $15.2M (flat YoY); net loss improved to $1.1M ($0.07/sh) from $2.4M loss.
- FY2022 revenue $57.0M (+6% YoY); net loss $7.5M ($0.47/sh) vs $5.2M ($0.34) in 2021.
- Record Cyclo G6 probe sales: 16,400 units in Q4 (+8% YoY); Q4 glaucoma product revenue $4.2M (+9%).
- Retina revenue $8.1M in Q4 (-11% YoY); full-year retina $31.7M (+2%).
- 2023 guidance: revenue $57-59M; Cyclo G6 probes 65k-67k units (9-12% growth); adjusting for ~$1.5M royalty reduction.

## SEC filing metadata
- accession: 0000950170-23-007036
- form_type: 8-K
- ticker: IRIX
- cik: 0001006045
- company_name: IRIDEX CORP
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006045/000095017023007036/0000950170-23-007036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006045/000095017023007036/irix-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007036
- JSON: https://secwatch.observer/filing/0000950170-23-007036.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007036.txt

## Key facts
- Earnings Releases
  IRIDEX CORP reported the three months ended December 31, 2022 results: revenue $15.2 million, net income $1.1 million, EPS $0.07 per share.
  - Period: the three months ended December 31, 2022
  - Revenue: $15.2 million
  - Net income: $1.1 million
  - EPS: $0.07 per share
  - Result: reported results
  source text: results for the fourth quarter and year ended December 31, 2022 and issued 2023 financial guidance. Fourth Quarter 2022 & Recent Highlights • Generated total revenue of $15.2 million, essentially unchanged from the prior year period • Cyclo G6® product family revenue of $4.2 million, an increase of 9% year-over-year o 16,400 Cyclo G6 probes sold, a quarterly
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006045/000095017023007036/0000950170-23-007036-index.htm
- Earnings Releases
  IRIDEX CORP reported full year 2023 results: revenue $57 million to $59 million. Guidance initiated.
  - Period: full year 2023
  - Revenue: $57 million to $59 million
  - Guidance: initiated
  - Result: guidance update
  source text: Total revenue for the full year is expected to be $57 million to $59 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006045/000095017023007036/0000950170-23-007036-index.htm
- Earnings Releases
  IRIDEX CORP reported the year ended December 31, 2022 results: revenue $57.0 million, net income $7.5 million, EPS $0.47 per share.
  - Period: the year ended December 31, 2022
  - Revenue: $57.0 million
  - Net income: $7.5 million
  - EPS: $0.47 per share
  - Result: reported results
  source text: 577 systems in February 2023 • Cash and cash equivalents totaled approximately $13.9 million as of December 31, 2022 Full Year 2022 Highlights • Generated total revenue of $57.0 million, an increase of 6% compared to 2021 • Cyclo G6 product family revenue of $14.7 million, an increase of 5% year-over-year • Sold 59,800 Cyclo G6 probes, compared to 58,200 in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006045/000095017023007036/0000950170-23-007036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.